Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study
暂无分享,去创建一个
S. Ahn | J. Yoon | B. Kim | Byungyoon Yun
[1] R. Gani,et al. Managing liver cirrhotic complications: Overview of esophageal and gastric varices , 2020, Clinical and molecular hepatology.
[2] J. H. Kim,et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop , 2020, Clinical and molecular hepatology.
[3] J. Ludvigsson,et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. , 2020, The New England journal of medicine.
[4] J. Bosch,et al. Cirrhosis as new indication for statins , 2020, Gut.
[5] Peng Luo,et al. Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection , 2020, The Journal of international medical research.
[6] D. J. Kim,et al. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017 , 2019, Clinical and molecular hepatology.
[7] J. Ludvigsson,et al. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population , 2019, Annals of Internal Medicine.
[8] J. Rehm,et al. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.
[9] T. Taddei,et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. , 2019, Gastroenterology.
[10] H. Kim,et al. Balance diagnostics after propensity score matching. , 2019, Annals of translational medicine.
[11] S. Kottilil,et al. Chronic Hepatitis B Infection: A Review , 2018, JAMA.
[12] A. Montano‐Loza,et al. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis , 2018, Current Treatment Options in Gastroenterology.
[13] Frank B. Hu,et al. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications , 2018, Nature Reviews Endocrinology.
[14] E. Kang,et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. , 2017, Journal of hepatology.
[15] Siddharth Singh,et al. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] T. Bannerman,et al. Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide , 2016, EBioMedicine.
[17] Ding‐Shinn Chen,et al. Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study , 2016, The American Journal of Gastroenterology.
[18] J. Bosch,et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. , 2016, Gastroenterology.
[19] J. Jose. Statins and its hepatic effects: Newer data, implications, and changing recommendations , 2016, Journal of pharmacy & bioallied sciences.
[20] Y. Saisho. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. , 2015, Endocrine, metabolic & immune disorders drug targets.
[21] G. Sitia,et al. Chronic hepatitis B: role of anti-platelet therapy in inflammation control , 2015, Cellular and Molecular Immunology.
[22] Anoop Misra. Ethnic-Specific Criteria for Classification of Body Mass Index: A Perspective for Asian Indians and American Diabetes Association Position Statement. , 2015, Diabetes technology & therapeutics.
[23] G. Garcı́a-Cardeña,et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins , 2014, Gut.
[24] Young Duk Song,et al. Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System , 2014, Diabetes & metabolism journal.
[25] Bum-Joon Kim. Hepatitis B virus mutations related to liver disease progression of Korean patients. , 2014, World journal of gastroenterology.
[26] J. Bosch,et al. Effects of simvastatin administration on rodents with lipopolysaccharide‐induced liver microvascular dysfunction , 2013, Hepatology.
[27] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[28] F. Lammert,et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.
[29] Yuzhi Zhang,et al. Flow Cessation Triggers Endothelial Dysfunction During Organ Cold Storage Conditions: Strategies for Pharmacologic Intervention , 2010, Transplantation.
[30] A. Szuba,et al. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver , 2010, Pharmacological reports : PR.
[31] J. Bosch,et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. , 2007, Journal of hepatology.
[32] Y. Kook,et al. Molecular Epidemiology of Hepatitis B Virus (HBV) Genotypes and Serotypes in Patients with Chronic HBV Infection in Korea , 2006, Intervirology.
[33] Anna Castiglione,et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.
[34] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[35] S. Grundy,et al. Ethnic-Specific Criteria for the Metabolic Syndrome , 2006, Diabetes Care.
[36] Yuzhi Zhang,et al. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. , 2005, The Journal of clinical investigation.
[37] Michal Abrahamowicz,et al. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. , 2005, American journal of epidemiology.
[38] C. Chu,et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. , 2004, The American journal of medicine.
[39] J. Rodés,et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. , 2004, Gastroenterology.
[40] J. Rodés,et al. Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic ischemia-reperfusion injury in the rat. , 2001, Transplantation.